MedTrace Logo

HRD and Resistance to PAPPi in EOC Patients

NCT05310370 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 400

Last updated 2022-04-04

No results posted yet for this study

Summary

The association between homologous recombination (HR) gene mutations and homologous recombination deficiency (HRD) status in Chinese epithelial ovarian cancer (EOC) patients has been investigated in previous studies (NCT04190667 and NCT04651920). This study is to investigate the correlation between HRD and the resistance to poly(ADP-ribose) polymerase inhibitors (PARPi) in a Chinese cohort confirmed of epithelial ovarian cancer. The mutated genes, HRD score model and their relationship with the prognosis is the primary endpoint in this study. All enrolled patients will accept PARPi as maintenance therapy after the complete or partial remission of targeted lesions. A multiple panel testing of germline and somatic genes, including BRCA1/2, and HRD score are provided for all participants.

Conditions

  • Epithelial Ovarian Cancer
  • Homologous Recombination Deficiency
  • Homologous Recombination Repair Gene Mutation
  • Poly(ADP-ribose) Polymerase Inhibitor
  • Drug Resistance
  • Progression-free Survival
  • Overall Survival

Interventions

GENETIC

Testing of homologous recombination deficiency

A multiple panel testing of germline and somatic genes, including BRCA1/2, and HRD score are provided for all participants.

Sponsors & Collaborators

  • Lei Li

    lead OTHER

Principal Investigators

  • Lei Li, M.D. · Peking Union Medical College Hospital

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-26
Primary Completion
2024-03-26
Completion
2025-03-26

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05310370 on ClinicalTrials.gov